Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Formic Acid→

Formic Acid Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
64-18-6
Molecular formula
CH2O2
Molecular weight
46.0254 g/mol
Drug class
Organic carboxylic acidchemical reagent and preservative, not a conventional therapeutic API
Mechanism of action
Dissociates in aqueous systems to release hydrogen ions and formate, acting as an acidifier and preservative in selected formulations. No established systemic therapeutic mechanism applies to formic acid itself.
Indications / reported uses
  • Used as a chemical reagent, acidifying agent and preservative in selected industrial, food and pharmaceutical processes; no general human therapeutic indication should be assigned

Sources: PubChem — Formic acid · ECHA — Formic acid substance information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Formic Acid Environmental Risk Assessment (ERA) (the Formic Acid ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.